Novartis recalled a single lot of valsartan, a blood pressure/heart failure drug the company sells under the brand name Diovan. According to the FDA, this is a Class II recall.

Researchers at Duke are hard at work on digital twins that could help care teams make important treatment decisions. 

TAVR can be especially challenging in patients with PAR and an enlarged LVOT. Specialists in China have developed a new technique that could improve outcomes for some of these patients without introducing new risks. 

Veteran cardiologist Jonathan Reiner, MD, a professor at George Washington University, shared his concerns about President Donald Trump's health. 

Waist circumference and waist-to-hip ratio both provide substantial value when evaluating a patient's risk of developing heart disease. “It is time to abandon a sole focus on BMI,” as Harlan M. Krumholz, MD, explained. 

Structural heart disease is just one of the many areas where cardiac CT is expected to expand in the near future.

The VueJect ultrasound contrast delivery system was designed to improve workflow efficiency and provide consistency from one user to the next.

The two companies want to spread the word about how daily habits can influence cardiovascular health.

Incidental lung findings can help identify TAVR patients who may require additional follow-up care after treatment. 

Robert Califf, MD, MACC, a veteran cardiologist, delivered the keynote speech at SCCT 2026 and then spoke to Cardiovascular Business about where the country's healthcare system is headed. 

Healthcare providers should return any unused devices to the manufacturer. 

The new-look ELANA device from AMT Medical could simplify CABG procedures and help improve patient access to minimally invasive and robotic surgical techniques.

DentaQuest, the second-largest dental benefits administrator in the U.S., suffered the record-setting cyberattack in May. A notorious ransomware gang has taken credit for the attack. 

The meteoric rise of large-language AI is quietly altering if not effectively upending scientific inquiry. It’s been doing so almost since the technology’s public debut in late 2022. And medical research has been anything but exempt.